-
Guangzhou Mygene Raises ‘Hundreds of Millions’ in Series C Financing Led by Efund Capital
•
China-based molecular diagnostic product developer Guangzhou Mygene Medical Technology Co., Ltd reportedly raised “hundreds of millions” of renminbi in a Series C financing round led by Efund Capital. Other investors included Anggu Fuge Investment, Juyo Capital, Benchi Capital, and Hongtu Runda Capital. The proceeds will be used for research and…
-
Biosion Completes Series B Financing Round Led by Guangfa Xinde Investment
•
Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases, has announced the completion of a Series B financing round at upwards of RMB 100 million (USD 14.33 million). The funding was led by Guangfa Xinde Investment, with contributions from FangFund, Addor Capital, and Suxin…
-
Shenzhen Würzburg Dynamics Raises RMB 100 Million in Series A Financing Round
•
China-based Shenzhen Würzburg Dynamics has reportedly raised RMB 100 million (USD 14.36 million) in a Series A financing round. The funding was led by 3E Bioventures Capital, with contributions from Tzitzit Asset and Fosun Health Capital. The proceeds will be used for research and development and market construction for multiple…
-
AcornMed Raises RMB 200 Million in Series B Financing Led by Yikai Venture Capital
•
AcornMed, a tumor precision medicine specialist based in Beijing, has reportedly raised RMB 200 million (USD 28.7 million) in a Series B financing round led by Yikai Venture Capital. Other investors included Lichen Investment, Qingdao Hongteng, and Wushi Capital. The proceeds will be used for research and development of tumor…
-
Jiangsu Vcare PharmaTech Raises RMB 200 Million in Series B Financing Round
•
China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67 million) in a Series B financing round. The round was led by Changjiang Venture Capital, with additional investments from Hongcheng Investment, Huadian Investment, Yangtze Investment, and SDIC. The proceeds will be used for clinical development…
-
Nanjing Pharmaceutical to Acquire Majority Stakes in Three Jiangsu Subsidiaries
•
China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%, 55%, and 100% stake in three subsidiaries of compatriot firm Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. The deals entail a consideration of RMB 148 million (USD 21.2 million). The subsidiaries involved are Suzhou Tianqing…
-
MSD and Kelun Biotech Ink Record-Breaking ADC Deal
•
Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest out-licensing deal between a multinational and a China-based firm. The US giant has returned to sign its third deal of this year with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, securing development, manufacturing, and commercialization rights to…
-
Biomica Raises Funds for Tumor Immunity and IBD Drug Development
•
Israel-based start-up Biomica has reportedly raised an undisclosed amount of money via another financing round, led by Shanghai HealthCare Capital and its parent company Evogene. The proceeds will be used for a Phase I clinical study for its tumor immunity project BMC128, GMPc-compliant manufacturing for BMC333 for inflammatory bowel disease…
-
Redpine Medical Raises ‘Hundreds of Millions’ in Series C Financing Round
•
Redpine Medical, a single-use endoscope maker based in Guangzhou, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round led by Yuexiu Industrial Investment Fund. Other investors included Eight Roads, Guoju Venture Capital, Caixin Private Placement, and others. The proceeds will be used for manufacturing capacity…
-
Sibionics Raises RMB 500 Million in Series D Financing Round
•
Shenzhen-based chronic disease device maker Sibionics has reportedly raised close to RMB 500 million (USD 71.7 million) in a Series D financing round. The round was led by Shanghai Healthcare Capital and Guangdong Traditional Chinese Medicine Healthcare Fund, with contributions from Industrial Securities Capital, Next Capital, and China New Town…
-
Waker Bioscience Raises Angel Funding for ISA Technology Upgrades
•
Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens of millions” of renminbi in an angel financing round, solely led by BGI Co-Win. The proceeds will be used for technology upgrades, team building, testing business development, and laboratory platform automation construction. Company Background and…
-
Ronovo Surgical Raises Pre-Series B Funding for Surgical Robot Development
•
Ronovo Surgical, a minimally invasive surgery device maker based in Shanghai, has reportedly raised “tens of millions” of US dollars in a Pre-Series B financing round led by LongRiver Investments. Other investors included Lilly Asia Ventures, Vivo Capital, Matrix Partners, and GGV Capital. The proceeds will be used for multi-specialty…
-
TowardPi Raises RMB 300 Million in Series C Financing Round
•
China-based ophthalmology device maker TowardPi (Beijing) Medical Technology Ltd has reportedly raised close to RMB 300 million (USD 42.96 million) in a Series C financing round. The round was led by Sunrock Capital, with contributions from Tao Capital, Kunlun Capital, and existing investor Aibo Qingshi Venture Capital. This marks a…
-
Endo International Licenses TLC’s Phase III Nanomedicine for OA Knee Pain
•
Ireland-based Endo International plc (NASDAQ: ENDP) has announced a licensing deal between its subsidiary Endo Ventures Ltd (EVL) and Taiwan Liposome Company Ltd (TLC). The agreement centers on TLC’s TLC599, a novel injectable nanomedicine compound currently in Phase III development for osteoarthritis (OA) knee pain. Deal Terms and FinancialsUnder the…
-
Meihua Medtech Secures Over RMB 100M in Series B Financing Led by Eight Roads and Sunland
•
China’s Zhuhai Meihua Medical Technology Co., Ltd, a leading clinical microbiology laboratory overall solutions provider, has reportedly raised over RMB 100 million (USD 14.3 million) in a Series B financing round. The round was led by Eight Roads and Sunland Fund, with contributions from Zhuhai Hi tech Financial Investment and…
-
InnerMedical Secures RMB 300M in Series D Funding Led by Green Pine and Simiao
•
InnerMedical Co., Ltd, a leading chronic disease diagnosis and treatment solutions provider based in Shenzhen, has reportedly raised close to RMB 300 million (USD 42.9 million) in a Series D financing round. The round was led by Green Pine Capital Partners and Simiao Capital, with participation from Cornerstone Investment, Chengshang…
-
Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine
•
China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept milestone for its mRNA rabies vaccine program. This new vaccine candidate for rabies post-exposure prophylactic was developed in partnership with Providence Therapeutics Holdings Inc., using a clinically validated mRNA technology platform. It can be used…
-
Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics
•
Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD 15 million, co-led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund. The proceeds will be used to leverage an innovative discovery platform and advance the company’s lead drug candidates to treat…
-
4B Technologies Raises RMB 100M in Pre-Series B Financing Round
•
China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development, reportedly raised upwards of RMB 100 million (USD 14.3 million) in a Pre-Series B financing round. Dachen Capital led the round, which included contributions from Huaxi Investment, FangSheng Capital, ZGC Co-Innovation Fund, and Tao Capital,…
-
Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech
•
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio’s proprietary All H2L2 transgenic Harbour Mice platform…
